AnewPharma

Quick facts

Phase 3 pipeline

• CM082 combined with everolimus · Oncology
  CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment.

Phase 2 pipeline

• CM082 plus JS001

Phase 1 pipeline

• [14]CM082 suspension
• CM082 plus paclitaxel
• CM082 with fed or fasting